Company CVAbout Supriya Lifescience Ltd 
Supriya Lifescience Ltd
Small Cap
Pharmaceuticals & Biotechnology
Supriya Lifescience Limited was initially constituted on October 29, 1985, as a "Partnership Firm under the name `M/s Supriya Chemicals'. The Partnership Firm was last re-constituted pursuant to a Partnership Deed dated November 30, 2007. Upon the conversion of `M/s Supriya Chemicals' the Partnership Firm into a Public Limited Company, the Company got incorporated as `Supriya Lifescience Limited' vide certified on March 26, 2008 by the Registrar of Companies, Mumbai.
Company Coordinates
No Company Details Available
Capital StructureCapital Structure
Present Equity Capital
INR 16.10 Cr
Number of Shares
8.05 Cr
Face Value
INR 2.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
23-Dec-2021
8.05
16.10
7299270
2
Public Issue
22-Dec-2021
8.05
16.10
7299270
2
Public Issue
26-Dec-2020
7.32
14.64
58546824
2
Stock Split
01-Oct-2015
1.46
14.64
9757804
2
Bonus Issue
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 8 Schemes (0.68%)
FIIs
Held by 69 FIIs (5.46%)
Promoter with highest holding
Satish Waman Wagh (67.64%)
Highest Public shareholder
Aditya Birla Sun Life Insurance Company Limited (2.15%)
Individual Investors Holdings
16.77%
Board of Directors
Management
Designation
Remuneration
Satish Waman Wagh
Chairman & Managing Director
12.94 cr
Smita Satish Wagh
Whole-time Director
1.43 cr
Soloni Satish Wagh
Whole-time Director
1.3 cr
Shivani Satish Wagh
Whole-time Director
1.3 cr
Balasahab Gulabrao Sawant
Whole-time Director
51.3 lacs
Kedar Shankar Karmarkar
Independent Director
3.3 lacs
Bhairav Manojbhai Chokshi
Independent Director
3.5 lacs
Dileep Kumar Jain
Independent Director
2.8 lacs
Dinesh N Modi
Independent Director
3.5 lacs
Neelam Yashpal Arora
Independent Director
2.7 lacs
Shweta Shivdhari Singh
Company Sec. & Compli. Officer
0
Manoj Deo Dorlikar
WTD & Additional Director
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
Cost of Material Consumed
232.436
0%
Cost of Material Consumed
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
No Data Available for Finished Goods Segmentation
No Data Available
Stock DNARevenue and Profits:
Net Sales:
200 Cr
(Quarterly Results - Sep 2025)
Net Profit:
50 Cr
Pharmaceuticals & Biotechnology
INR 5,995 Cr (Small Cap)
33.00
34
0.13%
-0.07
18.30%
6.01
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
